Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene in Recurrent Endometrial Cancer
NCT00004915Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Nov 1998
- Primary completion
- Feb 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raloxifene in endometrial cancer (EC), sponsored by Northwestern University. Primary endpoints: Response Rate and Time to Disease Progression. Started Nov 1998; status: completed.
02
Drugs
raloxifene
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00004915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004915.